Human brain sodium dependent inorganic phosphate cotransporter assay

ABSTRACT

This invention describes a novel human brain Na +  -dependent inorganic phosphate cotransporter, designated the hBNPI protein. This invention also encompasses nucleic acids encoding this protein, or a fragment thereof, as well as methods employing this protein and the nucleic acid compounds.

This application is a division of application Ser. No. 08/430,033, filedApr. 27, 1995.

BACKGROUND OF THE INVENTION

Inorganic phosphate (P_(i)), a charged anion, is essential tobioenergetics, metabolic regulation, and bone and membrane structure. Itis well known that P_(i) homeostasis in the body depends primarily onmechanisms that govern the renal excretion of P_(i) into the glomerularfiltrate and its subsequent reabsorption against an electrochemicalgradient via brush-border epithelial cells located in the proximaltubule of the kidney [J. Bonjour and J. Caverzasio, Reviews inPhysiological Pharmacoloy, 100:161-214 (1985); V. W. Dennis, Phosphatehomeostasis, in HANDBOOK OF PHYSIOLOGY, (S. Shultz, ed. 1991) at pages1785-1815.] This transepithelial transport of P_(i) is mediated, inpart, by a transport system which is driven by the transmembrane Na⁺gradient across the microvilli brush border membrane. However, itremains largely unknown how cells transport and regulate necessary theintracellular concentrations of P_(i), and the molecular eventsunderlying this system. Experiments using isolated kidney tubules orbrush-border membranes have shown that P_(i) transport is rathercomplex, regulated not only by extracellular [P_(i) ] but also byneurotransmitters such as catecholamines (for review see V. W. Dennis,supra), and by a variety of hormones and metabolic factors. Berndt andKnox, "Renal Regulation of Phosphate Excretion", in THE KIDNEY.PHYSIOLOGY AND PATHOPHYSIOLOGY, (D. W. Seldin and G. Giebisch, eds.,1991) at pages 1381-1396. Renal denervation, for example, decreasessodium and phosphate reabsorption. Norepinephrine released from nerveendings in proximity to renal tubules acts on the proximal tubule toincrease phosphate reabsorption. In studies of isolated tubules,however, dopamine is shown to inhibit phosphate and sodium transport inthe rabbit proximal tubule. Furthermore, several studies also show thatdepletion of extracellular P_(i) or increased circulating levels ofparathyroid hormone alter the activity and expression of transportermolecules or both.

Several recent reports have demonstrated that P_(i) homeostasissignificantly affects the central nervous system (CNS).Phosphate/calcium alterations in serum, for example, have beenimplicated in the etiology and pathogenesis of Alzheimer's diseases.Depletion of high energy phosphates (phosphocreatine) and ATP is thoughtto be part of the final common pathway mediating excitotoxic neuronalcell death secondary to a wide variety of insults. Tight couplingbetween P_(i) transport and ATP production has been observed in manycells and tissues. Chronic P_(i) depletion in vivo is associated with asignificant reduction in the ATP content of polymorphonuclearleukocytes, platelets, and various tissues including kidney, heart, andskeletal muscle. A similar observation has been made in culturedperipheral vagal nerves. This reduction in intracellular ATP has beenshown to be a direct consequence of the decrease in intracellular P_(i)which occurs following P_(i) depletion. In addition to its possible rolein ATP biosynthesis, several lines of evidence have suggested that P_(i)may be involved in neuronal signalling events. In this regard, a studyusing brain tissue has recently shown that physiological concentrationsof P_(i) can enhance the ATP-dependent binding of Ca⁺⁺ to brainmicrosomes, resulting in a larger intracellular pool of Ca⁺⁺ releasableby inositol triphosphate. Our recent work have demonstrated that >90%P_(i) transport in cortical neurons, which displays similar kineticparameters to those reported for cultured kidney proximal tubuleepithelial cells and membrane vesicles, are sodium dependent and thatthis Na⁺ -dependent transport system is regulated through a Na⁺-dependent P_(i) cotransporter. B. Ni, et al,, Proceedings of theNational Academy of Sciences (U.S.A.), 91:5607-5611 (1994).

The present invention describes the cloning and characterization of ahuman brain Na⁺ -dependent P_(i) cotransporter which is selectivelyexpressed in discrete populations of neurons and glia. Fluorescent insitu hybridization (FISH) analysis demonstrates that this Na⁺ -dependentP_(i) cotransporter is located in chromosome 19 (19q13.3) which has beenlinked to susceptible gene(s) for late onset Alzheimer's disease. M.Mullan and F. Crawford, Trends in Neurological Sciences, 16, 398-403(1993). The characterization and treatment of physiological disorders mshereby furthered.

SUMMARY OF THE INVENTION

This invention provides an isolated amino acid compound useful as ahuman brain sodium-dependent inorganic phosphate cotransporter, saidcompound comprising the amino acid sequence ##STR1## hereinafterdesignated as SEQ ID NO:2.

The invention also provides an isolated nucleic acid compound thatcomprises a nucleic acid sequence which encodes for the amino acidcompounds provided. Particularly this invention provides the isolatednucleic acid compound having the sequence ##STR2## which is hereinafterdesignated as SEQ ID NO:1.

This invention also provides recombinant nucleic acid vectors comprisingnucleic acids encoding SEQ ID NO:2. This invention also encompassesrecombinant DNA vectors which comprise the isolated DNA sequence whichis SEQ ID NO:1.

The present invention also provides assays for determining the efficacyand adverse reaction profile of agents useful in the treatment orprevention of disorders associated with an inappropriate stimulation ofa human brain Na⁺ -dependent inorganic phosphate cotransporter.

DETAILED DESCRIPTION AND PREFERRED EMBODIMENTS

The terms and abbreviations used in this document have their normalmeanings unless otherwise designated. For example "°C." refers todegrees Celsius; "N" refers to normal or normality; "mmol" refers tomillimole or millimoles; "g" refers to gram or grams; "ml" meansmilliliter or milliliters; "M" refers to molar or molarity; "μg" refersto microgram or micrograms; and "μl" refers to microliter ormicroliters.

All nucleic acid sequences, unless otherwise designated, are written inthe direction from the 5' end to the 3' end, frequently referred to as"5' to 3'".

All amino acid or protein sequences, unless otherwise designated, arewritten commencing with the amino terminus ("N-terminus") and concludingwith the carboxy terminus ("C-terminus").

"Base pair" or "bp" as used herein refers to DNA or RNA. Theabbreviations A,C,G, and T correspond to the 5'-monophosphate forms ofthe deoxyribonucleosides (deoxy)adenine, (deoxy)cytidine,(deoxy)guanine, and (deoxy)thymine, respectively, when they occur in DNAmolecules. The abbreviations U,C,G, and T correspond to the5'-monophosphate forms of the ribonucleosides uracil, cytidine, guanine,and thymine, respectively when they occur in RNA molecules. In doublestranded DNA, base pair may refer to a partnership of A with T or C withG. In a DNA/RNA, heteroduplex base pair may refer to a partnership of Awith U or C with G. (See the definition of "complementary", infra.)

The terms "digestion" or "restriction" of DNA refers to the catalyticcleavage of the DNA with a restriction enzyme that acts only at certainsequences in the DNA ("sequence-specific endonucleases"). The variousrestriction enzymes used herein are commercially available and theirreaction conditions, cofactors, and other requirements were used aswould be known to one of ordinary skill in the art. Appropriate buffersand substrate amounts for particular restriction enzymes are specifiedby the manufacturer or can be readily found in the literature.

"Ligation" refers to the process of forming phosphodiester bonds betweentwo double stranded nucleic acid fragments. Unless otherwise provided,ligation may be accomplished using known buffers and conditions with aDNA ligase, such as T4 DNA ligase.

The term "plasmid" refers to an extrachromosomal (usually)self-replicating genetic element. Plasmids are generally designated by alower case "p" preceded and/or followed by letters and/or numbers. Thestarting plasmids herein are either commercially available, publiclyavailable on an unrestricted basis, or can be constructed from availableplasmids in accordance with published procedures. In addition,equivalent plasmids to those described are known in the art and will beapparent to the ordinarily skilled artisan.

The term "reading frame" means the nucleotide sequence from whichtranslation occurs "read" in triplets by the translational apparatus oftransfer RNA (tRNA) and ribosomes and associated factors, each tripletcorresponding to a particular amino acid. A base pair insertion ordeletion (termed a frameshift mutation) may result in two differentproteins being coded for by the same DNA segment. To insure againstthis, the triplet codons corresponding to the desired polypeptide mustbe aligned in multiples of three from the initiation codon, i.e. thecorrect "reading frame" being maintained.

"Recombinant DNA cloning vector" as used herein refers to anyautonomously replicating agent, including, but not limited to, plasmidsand phages, comprising a DNA molecule to which one or more additionalDNA segments can or have been added.

The term "recombinant DNA expression vector" as used herein refers toany recombinant DNA cloning vector in which a promoter to controltranscription of the inserted DNA has been incorporated.

The term "expression vector system" as used herein refers to arecombinant DNA expression vector in combination with one or moretrans-acting factors that specifically influence transcription,stability, or replication of the recombinant DNA expression vector. Thetrans-acting factor may be expressed from a co-transfected plasmid,virus, or other extrachromosomal element, or may be expressed from agene integrated within the chromosome.

"Transcription" as used herein refers to the process whereby informationcontained in a nucleotide sequence of DNA is transferred to acomplementary RNA sequence.

The term "transfection" as used herein refers to the taking up of anexpression vector by a host cell whether or not any coding sequences arein fact expressed. Numerous methods of transfection are known to theordinarily skilled artisan, for example, calcium phosphateco-precipitation, and electroporation. Successful transfection isgenerally recognized when any indication of the operation of this vectoroccurs within the host cell.

The term "transformation" as used herein means the introduction of DNAinto an organism so that the DNA is replicable, either as anextrachromosomal element or by chromosomal integration. Methods oftransforming bacterial and eukaryotic hosts are well known in the art,many of which methods, such as nuclear injection, protoplast fusion orby calcium treatment using calcium chloride are summarized in J.Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL, (1989).

The term "translation" as used herein refers to the process whereby thegenetic information of messenger RNA is used to specify and direct thesynthesis of a polypeptide chain.

The term "vector" as used herein refers to a nucleic acid compound usedfor the transformation of cells in gene manipulation bearingpolynucleotide sequences corresponding to appropriate protein moleculeswhich when combined with appropriate control sequences confer specificproperties on the hose cell to be transformed. Plasmids, viruses, andbacteriophage are suitable vectors. Artificial vectors are constructedby cutting and joining DNA molecules from different sources usingrestriction enzymes and ligases. The term "vector" as used hereinincludes Recombinant DNA cloning vectors and Recombinant DNA expressionvectors.

The terms "complementary" or "complementarity" as used herein refers topair of bases, purines and pyrimidines, chat associate through hydrogenbonding in double stranded nucleic acid. The following base pairs arecomplementary: guanine and cytosine; adenine and thymine; and adenineand uracil.

The term "hybridization" as used herein refers to a process in which astrand of nucleic acid joins with a complementary strand through basepairing. The conditions employed in the hybridization of twonon-identical, but very similar, complementary nucleic acids varies withthe degree of complementarity of the two strands and the length of thestrands. Such techniques and conditions are well known to practitionersin this field.

"Isolated amino acid sequence" refers to any amino acid sequence,however constructed or synthesized, which is locationally distinct fromthe naturally occurring sequence.

"Isolated DNA compound" refers to any DNA sequence, however constructedor synthesized, which is locationally distinct from its natural locationin genomic DNA.

"Isolated nucleic acid compound" refers to any RNA or DNA sequence,however constructed or synthesized, which is locationally distinct fromits natural location.

A "primer" is a nucleic acid fragment which functions as an initiatingsubstrate for enzymatic or synthetic elongation.

The term "promoter" refers to a DNA sequence which directs transcriptionof DNA to RNA.

A "probe" as used herein is a nucleic acid compound or a fragmentthereof which hybridizes with a nucleic acid compound which encodeseither the entire sequence SEQ ID NO:2, a sequence complementary to SEQID NO:2, or a part thereof.

The term "stringency" refers to a set of hybridization conditions whichmay be varied in order to vary the degree of nucleic acid affinity forother nucleic acid. (See the definition of "hybridizedion", supra.)

The term "antigenically distinct" as used herein refers to a situationin which antibodies raised against an epitope of the proteins of thepresent invention, or a fragment thereof, may be used to differentiatebetween the proteins of the present invention and other brain Na⁺-dependent inorganic phosphate cotransporter subtypes. This term mayalso be employed in the sense that such antibodies may be used todifferentiate between the human hBNPI protein protein and analogousproteins derived from other species.

The term "PCR" as used herein refers to the widely-known polymerasechain reaction employing a thermally-stable polymerase.

Skilled artisans will recognize that the proteins of the presentinvention can be synthesized by a number of different methods. All ofthe amino acid compounds of the invention can be made by chemicalmethods well known in the art, including solid phase peptide synthesis,or recombinant methods. Both methods are described in U.S. Pat. No.4,617,149, the entirety of which is herein incorporated by reference.

The principles of solid phase chemical synthesis of polypeptides arewell known in the art and may be found in general texts in the area.See. e.g., H. Dugas and C. Penney, BIOORGANIC CHEMISTRY, (1981) at pages54-92. For examples, peptides may be synthesized by solid-phasemethodology utilizing an Applied Biosystems 430A peptide synthesizer(commercially available from Applied Biosystems, Foster City Calif.) andsynthesis cycles supplied by Applied Biosystems. Protected amino acids,such as t-butoxycarbonyl-protected amino acids, and other reagents arecommercially available from many chemical supply houses.

Sequential c-butoxycarbonyl chemistry using double couple protocols areapplied to the starting p-methyl benzhydryl amine resins for theproduction of C-terminal carboxamides. For the production of C-terminalacids, the corresponding pyridine-2-aldoxime methiodide resin is used.Asparagine, glutamine, and arginine are coupled using preformed hydroxybenzotriazole esters. The following side chain protection may be used:

Arg, Tosyl

Asp, cyclohexyl

Glu, cyclohexyl

Set, Benzyl

Thr, Benzyl

Tyr, 4-bromo carbobenzoxy

Removal of the t-butoxycarbonyl moiety (deprotection) may beaccomplished with trifluoroacetic acid (TFA) in methylene chloride.Following completion of the synthesis the peptides may be deprotectedand cleaved from the resin with anhydrous hydrogen fluoride containing10% meta-cresol. Cleavage of the side chain protecting group(s) and ofthe peptide from the resin is carried out at zero degrees centigrade orbelow, preferably -20° C. for thirty minutes followed by thirty minutesat 0° C.

After removal of the hydrogen fluoride, the peptide/resin is washed withether, and the peptide extracted with glacial acetic acid and thenlyophilized. Purification is accomplished by size-exclusionchromatography on a Sephadex G-10 (Pharmacia) column in 10% acetic acid.

The proteins of the present invention may also be produced byrecombinant methods. Recombinant methods are preferred if a high yieldis desired. A general method for the construction of any desired DNAsequence is provided in J. Brown, et al., Methods in Enzymoloy, 68:109(1979). See also, J. Sambrook, et al., supra.

The basic steps in the recombinant production of desired proteins are:

a) construction of a synthetic or semi-synthetic DNA encoding theprotein of interest;

b) integrating said DNA into an expression vector in a manner suitablefor the expression of the protein of interest, either alone or as afusion protein;

c) transforming an appropriate eukaryotic or prokaryotic host cell withsaid expression vector,

d) culturing said transformed or transfected host cell in a manner toexpress the protein of interest; and

e) recovering and purifying the recombinantly produced protein ofinterest.

In general, prokaryotes are used for cloning of DNA sequences inconstructing the vectors of this invention. Prokaryotes may also beemployed in the production of the protein of interest. For example, theEscherichia coli K12 strain 294 (ATCC No. 31446) is particularly usefulfor the prokaryotic expression of foreign proteins. Other strains of E.coli which may be used (and their relevant genotypes) include thefollowing.

    ______________________________________                                        Strain    Genotype                                                            ______________________________________                                        DH5α                                                                              F.sup.-  (φ80dlacZΔM15), Δ(lacZYA-argF)U169                   supE44, λ.sup.-, hsdR17(r.sub.K.sup.-, m.sub.K.sup.+),                 recA1,                                                                        endA1, gyrA96, thi-1, relA1                                         HB101     supE44, hsdS20(r.sub.B.sup.-  m.sub.B.sup.-), recA13, ara-                    14, proA2 lacY1, galK2, rspL20, xyl-5,                                        mtl-1, mcrB, mrr                                                    JM109     recA1, e14.sup.- (mcrA), supE44, endA1,                                       hsdR17(r.sub.K.sup.-, m.sub.K.sup.+), gyrA96, relA1, thi-                     1, Δ(lac-proAB), F'[traD36, proAB+                                      lacI.sup.q,lacZΔM15]                                          RR1       supE44, hsdS20(r.sub.B.sup.-  m.sub.B.sup.-), ara-14 proA2,                   lacY1, galK2, rpsL20, xyl-5, mtl-5                                  χ1776 F.sup.-, ton, A53, dapD8, minA1, supE42                                       (glnV42), Δ(gal-uvrB)40, minB2, rfb-                                    2, gyrA25, thyA142, oms-2, metC65,                                            oms-1, Δ(bioH-asd)29, cycB2, cycA1,                                     hsdR2, λ.sup.-                                               294       endA, thi.sup.-, hsr.sup.-, hsm.sub.k.sup.+  (U.S. Pat. No.                   4,366,246)                                                          LE392     F.sup.-, hsdR514 (r.sup.- m.sup.-), supE44, supF58,                           lacY1, or Δlac(I--Y)6, galK2, glaT22,                                   metB1, trpR55, λ.sup.-                                       ______________________________________                                    

These strains are all commercially available from suppliers such as:Bethesda Research Laboratories, Gaithersburg, Md. 20877 and StratageneCloning Systems, La Jolla, Calif. 92037; or are readily available to thepoblic from sources such as the American Type Culture Collection, 12301Parklawn Drive, Rockville, Md., 10852-1776.

Except where otherwise noted, these bacterial strains can be usedinterchangeably. The genotypes listed are illustrative of many of thedesired characteristics for choosing a bacterial host and are not meantto limit the invention in any way. The genotype designations are inaccordance with standard nomenclature. See, for example, J. Sambrook, etal., supra. A preferred strain of E. coli employed in the cloning andexpression of the genes of this invention is RV308, which is availablefrom the ATCC under accession number ATCC 31608, and is described inU.S. Pat. No. 4,551,433, issued Nov. 5, 1985.

In addition to the strains of E. coli discussed supra, bacilli such asBacillus subtilis, other enterobacteriaceae such as Salmonellatyphimurium or Serratia marcescans, and various Pseudomonas species maybe used. In addition to these gram-negative bacteria, other bacteria,especially Streptomyces, spp., may be employed in the prokaryoticcloning and expression of the proteins of this invention.

Promoters suitable for use with prokaryotic hosts include theβ-lactamase [vector pGX2907 (ATCC 39344) contains the replicon andβ-lactamase gene] and lactose promoter systems [Chang et al., Nature(London), 275:615 (1978); and Goeddel et al., Nature (London), 281:544(1979)], alkaline phosphatase, the tryptophan (trp) promoter system[vector pATH1 (ATCC 37695) is designed to facilitate expression of anopen reading frame as a trpE fusion protein under control of the trppromoter] and hybrid promoters such as the tac promoter (isolatable fromplasmid pDR540 ATCC-37282). However, other functional bacterialpromoters, whose nucleotide sequences are generally known, enable one ofskill in the art to ligate them to DNA encoding the proteins of theinstant invention using linkers or adapters to supply any requiredrestriction sites. Promoters for use in bacterial systems also willcontain a Shine-Dalgarno sequence operably linked to the DNA encodingthe desired polypeptides. These examples are illustrative rather thanlimiting.

The proteins of this invention may be synthesized either by directexpression or as a fusion protein comprising the protein of interest asa translational fusion with another protein or peptide which may beremovable by enzymatic or chemical cleavage. It is often observed in theproduction of certain peptides in recombinant systems that expression asa fusion protein prolongs the lifespan, increases the yield of thedesired peptide, or provides a convenient means of purifying the proteinof interest. A variety of peptidases (e.g. trypsin) which cleave apolypeptide at specific sites or digest the peptides from the amino orcarboxy termini (e.g. diaminopeptidase) of the peptide chain are known.Furthermore, particular chemicals (e.g. cyanogen bromide ) will cleave apolypeptide chain at specific sites. The skilled artisan will appreciatethe modifications necessary to the amino acid sequence (and synthetic orsemi-synthetic coding sequence if recombinant means are employed) toincorporate site-specific internal cleavage sites. See e.g., P. Carter,"Site Specific Proteolysis of Fusion Proteins", Chapter 13 in PROTEINPURIFICATION: FROM MOLECULAR MECHANISMS TO LARGE SCALE PROCESSES,American Chemical Society, Washington, D.C. (1990).

In addition to cloning and expressing the genes of interest in theprokaryotic systems discussed above, the proteins of the presentinvention may also be produced in eukaryotic systems. The presentinvention is not limited to use in a particular eukaryotic host cell. Avariety of eukaryotic host cells are available from depositories such asthe American Type Culture Collection (ATCC) and are suitable for usewith the vectors of the present invention. The choice of a particularhost cell depends to some extent on the particular expression vectorused to drive expression of the nucleic acids of the present invention.Exemplary host cells suitable for use in the present invention arelisted in Table I.

                  TABLE I                                                         ______________________________________                                        Host Cell                                                                              Origin             Source                                            ______________________________________                                        HepG-2   Human Liver Hepatoblastoma                                                                       ATCC HB 8065                                      CV-1     African Green Monkey Kidney                                                                      ATCC CCL 70                                       LLC-MK.sub.2                                                                           Rhesus Monkey Kidney                                                                             ATCC CCL 7.1                                      3T3      Mouse Embryo Fibroblasts                                                                         ATCC CCL 92                                       CHO-K1   Chinese Hamster Ovary                                                                            ATCC CCL 61                                       HeLa     Human Cervix Epitheloid                                                                          ATCC CCL 2                                        RPMI8226 Human Myeloma      ATCC CCL 155                                      H4IIEC3  Rat Hepatoma       ATCC CCL 1600                                     C127I    Mouse Fibroblast   ATCC CCL 1616                                     HS-Sultan                                                                              Human Plasma Cell  ATCC CCL 1484                                              Plasmocytoma                                                         BHK-21   Baby Hamster Kidney                                                                              ATCC CCL 10                                       ______________________________________                                    

An especially preferred cell line employed in this invention is thewidely available cell line AV12-664 (hereinafter "AV12"). This cell lineis available from the American Type Culture Collection under theaccession number ATCC CRL 9595. The AV12 cell line was constructed byinjecting a Syrian hamster in the scruff of the neck with humanadenovirus 12 and isolating cells from the resulting tumor.

A wide variety of vectors, some of which are discussed below, exists forthe transformation of such mammalian host cells, but the specificvectors described herein are in no way intended to limit the scope ofthe present invention.

The pSV2-type vectors comprise segments of the simian virus 40 (SV40)genome that constitute a defined eukaryotic transcription unit-promoter,intervening sequence, and polyadenylation site. In the absence of theSV40 T antigen, the plasmid pSV2-type vectors transform mammalian andother eukaryotic host cells by integrating into the hose cellchromosomal DNA. A large number of plasmid pSV2-type vectors have beenconstructed, such as plasmid pSV2-gpt, pSV2-neo, pSV2-dhfr, pSV2-hyg,and pSV2-β-globin, in which the SV40 promoter drives transcription of aninserted gene. These vectors are suitable for use with the codingsequences of the present invention and are widely available from sourcessuch as the ATCC or the Northern Regional Research Laboratory (NRRL),1815 N. University Street, Peoria, Ill., 61604.

The plasmid pSV2-dhfr (ATCC 37146) comprises a murine dihydrofolatereductase (dhfr) gene under the control of the SV40 early promoter.Under the appropriate conditions, the dhfr gene is known to beamplified, or copied, in the host chromosome. This amplification canresult in the amplification of closely-associated DNA sequences and can,therefore, be used to increase production of a protein of interest. See,e.g., J. Schimke, Cell, 35:705-713 (1984).

Plasmids constructed for expression of the proteins of the presentinvention in mammalian and other eukaryotic host cells can utilize awide variety of promoters. The present invention is in no way limited tothe use of the particular promoters exemplified herein. Promoters suchas the SV40 late promoter, promoters from eukaryotic genes, such as, forexample, the estrogen-inducible chicken ovalbumin gene, the interferongenes, the gluco-corticoid-inducible tyrosine aminotransferase gene, andthe thymidine kinase gene, and the major early and late adenovirus genescan be readily isolated and modified to express the genes of the presentinvention. Eukaryotic promoters can also be used in tandem to driveexpression of a coding sequence of this invention. Furthermore, a largenumber of retroviruses are known that infect a wide range of eukaryotichost cells. The long terminal repeats in the retroviral DNA frequentlyencode functional promoters and, therefore, may be used to driveexpression of the nucleic acids of the present invention.

Plasmid pRSVcat (ATCC 37152) comprises portions of a long terminalrepeat of the Rots Sarcoma virus, a virus known to infect chickens andother host cells. This long terminal repeat contains a promoter which issuitable for use in the vectors of this invention. H. Gorman, et al.,Proceedings of the National Academy of Sciences (U.S.A.), 79:6777(1982). The plasmid pMSVi (MARL B-15929) comprises the long terminalrepeats of the Murine Sarcoma virus, a virus known to infect mouse andother host cells. The mouse metallothionein promoter has also been wellcharacterized for use in eukaryotic host cells and is suitable for usein the expression of the nucleic acids of the present invention. Themouse metallothionein promoter is present in the plasmid pdBPV-MMTneo(ATCC 37224) which can serve as the starting material of other plasmidsof the present invention.

An especially preferred expression vector system employs one of a seriesof vectors containing the BK enhancer, an enhancer derived from the BKvirus, a human papovavirus. The most preferred such vector systems arethose which employ not only the BK enhancer but also theadenovirus-2-early region 1A (E1A) gone product. The E1A gone product(actually, the E1A gone produces two products, which are collectivelyreferred to herein as "the E1A gone product") is an immediate-early goneproduct of adenovirus, a large DNA virus.

A most preferred expression vector employed in the present invention isthe phd series of vectors which comprise a BK enhancer in tandem withthe adenovirus late promoter to drive expression of useful products ineukaryotic host cells. The construction and method of using the phdplasmid, as well as related plasmids, are described in U.S. Pat. No.5,242,688, issued Sep. 7, 1993, and U.S. Pat. No. 4,992,373, issued Feb.12, 1991, as well as co-pending U.S. patent application No. 07/368,700,all of which are herein incorporated by reference. Escherichia coli K12GM48 cells harboring the plasmid phd are available as part of thepermanent stock collection of the Northern Regional Research Laboratoryunder accession number NRRL B-18525. The plasmid may be isolated fromthis culture using standard techniques.

The plasmid phd contains a unique BclI site which may be utilized forthe insertion of the gene encoding the protein of interest. The skilledartisan understands that linkers or adapters may be employed in cloningthe gene of interest into this BclI site. A depiction of the plasmid phdis provided as FIG. 2 of this document. The phd series of plasmidsfunctions most efficiently when introduced into a host cell whichproduces the E1A gene product, cell lines such as AV12-664,293 cells,and others, described supra.

Transformation of the mammalian cells can be performed by any of theknown processes including, but not limited to, the protoplast fusionmethod, the calcium phosphate co-precipitation method, electroporationand the like. See, e.g., J. Sambrook, et al,, supra, at 3:16.30-3:16.66.

Other routes of production are well known to skilled artisans. Inaddition to the plasmid discussed above, it is well known in the artthat some viruses are also appropriate vectors. For example, theadenovirus, the adeno-associated virus, the vaccinia virus, the herpesvirus, the baculovirus, and the rous sarcoma virus are useful. Such amethod is described in U.S. Pat. No. 4,775,624, herein incorporated byreference. Several alternate methods of expression are described in J.Sambrook, et al., supra, at 16.3-17.44.

In addition to prokaryotes and mammalian host cells, eukaryotic microbessuch as yeast cultures may also be used. The imperfect fungusSaccharomyces cerevisiae, or common baker's yeast, is the most commonlyused eukaryotic microorganism, although a number of other strains arecommonly available. For expression in Saccharomyces sp., the plasmidYRD7 (ATCC-40053), for example, is commonly used. See, e.g., L.Stinchcomb, et al., Nature, 282:39 (1979); J. Kingsman et al., Gene,7:141 (1979); S. Tschemper et al., Gene, 10:157 (1980). This plasmidalready contains the gene which provides a selectable marker for amutant strain of yeast lacking the ability to grow in tryptophan.

Suitable promoting sequences for use with yeast hosts include thepromoters for 3-phosphoglycerate kinase [found on plasmid pAP12BD (ATCC53231) and described in U.S. Pat. No. 4,935,350, issued Jun. 19, 1990,herein incorporated by reference] or other glycolytic enzymes such asenolase [found on plasmid pAC1 (ATCC 39532)], glyceraldehyde-3-phosphatedehydrogenase [derived from plasmid pHcGAPC1 (ATCC 57090, 57091)],hexokinase, pyruvate decarboxylase, phosphofructokinase,glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvanekinase, triosephosphate isomerase, phosphoglucose isomerase, andglucokinase, as well as the alcohol dehydrogenase and pyruvatedecarboxylase genes of Zymomonas mobilis (U.S. Pat. No. 5,000,000 issuedMar. 19, 1991, herein incorporated by reference).

Other yeast promoters, which are inducible promoters, having theadditional advantage of their transcription being controllable byvarying growth conditions, are the promoter regions for alcoholdehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymesassociated with nitrogen metabolism, metallothionein [contained onplasmid vector pCL28XhoLHBPV (ATCC 39475) and described in U.S. Pat. No.4,840,896, herein incorporated by reference], glyceraldehyde 3-phosphatedehydrogenase, and enzymes responsible for maltose and galactose [e.g.GAL1 found on plasmid pRY121 (ATCC 37658)] utilization. Suitable vectorsand promoters for use in yeast expression are further described in R.Hitzeman et al., European Patent Publication No. 73,657A. Yeastenhancers such as the UAS Gal from Saccharomyces cerevisiae (found inconjuction with the CYC1 promoter on plasmid YEpsec--hI1beta ATCC67024), also are advantageously used with yeast promoters.

Practitioners of this invention realize that, in addition to theabove-mentioned expression systems, the cloned cDNA may also be employedin the production of transgenic animals in which a test mammal, usuallya mouse, in which expression or overexpression of the proteins of thepresent invention can be assessed. The nucleic acids of the presentinvention may also be employed in the construction of "knockout" animalsin which the expression of the native cognate of the gene is suppressed.

Skilled artisans also recognize that some alterations of SEQ ID NO:2will fail to change the function of the amino acid compound. Forinstance, some hydrophobic amino acids may be exchanged for otherhydrophobic amino acids. Those altered amino acid compounds which confersubstantially the same function in substantially the same manner as theexemplified amino acid compound are also encompassed within the presentinvention. Typical such conservative substitutions attempt to preservethe: (a) secondary or tertiary structure of the polypeptide backbone;(b) the charge or hydrophobicity of the residue; or (c) the bulk of theside chain. Some examples of such conservative substitutions of aminoacids, resulting in the production of proteins which are functionalequivalents of the protein of SEQ ID NO:2 are shown in Table II, infra.

                  TABLE II                                                        ______________________________________                                        Original Residue  Exemplary Substitutions                                     ______________________________________                                        Ala               Ser, Gly                                                    Arg               Lys                                                         Asn               Gln, His                                                    Asp               Glu                                                         Cys               Ser                                                         Gln               Asn                                                         Glu               Asp                                                         Gly               Pro, Ala                                                    His               Asn, Gln                                                    Ile               Leu, Val                                                    Leu               Ile, Val                                                    Lys               Arg, Gln, Glu                                               Mel               Leu, Ile                                                    Phe               Met, Leu, Gyr                                               Ser               Thr                                                         Thr               Ser                                                         Trp               Tyr                                                         Tyr               Trp, Phe                                                    Val               Ile, Leu                                                    ______________________________________                                    

These substitutions may be introduced into the protein in a variety ofways, such as during the chemical synthesis or by chemical modificationof an amino acid side chain after the protein has been prepared.

Alterations of the protein having a sequence which corresponds to thesequence of SEQ ID NO:2 may also be induced by alterations of thenucleic acid compounds which encodes these proteins. These mutations ofthe nucleic acid compound may be generated by either random mutagenesistechniques, such as those techniques employing chemical mutagens, or bysite-specific mutagenesis employing oligonucleotides. Those nucleic acidcompounds which confer substantially the same function in substantiallythe same manner as the exemplified nucleic acid compounds are alsoencompassed within the present invention.

Other embodiments of the present invention are nucleic acid compoundswhich comprise isolated nucleic acid sequences which encode SEQ ID NO:2.As skilled artisans will recognize, the amino acid compounds of theinvention can be encoded by a multitude of different nucleic acidsequences because most of the amino acids are encoded by more than onenucleic acid triplet due to the degeneracy of the amino acid code.Because these alternative nucleic acid sequences would encode the sameamino acid sequences, the present invention further comprises thesealternate nucleic acid sequences.

The gene encoding the hBNPI protein molecule may be produced usingsynthetic methodology. This synthesis of nucleic acids is well known inthe art. See, e.g., E. L. Brown, R. Belagaje, M. J. Ryan, and H. G.Khorana, Methods in Enzymology, 68:109-151 (1979). The DNA segmentscorresponding to the receptor gene are generated using conventional DNAsynthesizing apparatus such as the Applied Biosystems Model 380A or 380BDNA synthesizers (commercially available from Applied Biosystems, Inc.,850 Lincoln Center Drive, Foster City, Calif. 94404) which employphosphoramidite chemistry. In the alternative, the more traditionalphosphotriester chemistry may be employed to synthesize the nucleicacids of this invention. [See, e.g., M. J. Gait, ed., OLIGONUCLEOTIDESYNTHESIS, A PRACTICAL APPROACH, (1984).]

The synthetic human hBNPI protein gene may be designed to possessrestriction endonuclease cleavage sites at either end of the transcriptto facilitate isolation from and integration into expression andamplification plasmids. The choice of restriction sites are chosen so asto properly orient the coding sequence of the receptor with controlsequences to achieve proper in-frame reading and expression of the hBNPIprotein. A variety of other such cleavage sites may be incorporateddepending on the particular plasmid constructs employed and may begenerated by techniques well known in the art.

In an alternative methodology, the desired DNA sequences can begenerated using the polymerase chain reaction as described in U.S. Pat.No. 4,889,818, which is herein incorporated by reference.

In addition to the deoxyribonucleic acid of SEQ ID NO:1, this inventionalso provides ribonucleic acids (RNA) which comprise the RNA sequence##STR3## hereinafter referred to as SEQ ID NO:3, or the complementaryribonucleic acid, or a fragment to either SEQ ID NO:3 or the complementthereof. The ribonucleic acids of the present invention may be preparedusing the polynucleotide synthetic methods discussed supra or they maybe prepared enzymatically using RNA polymerases to transcribe a DNAtemplate. complement thereof.

The most preferred systems for preparing the ribonucleic acids of thepresent invention employ the RNA polymerase from the bacteriophage T7 orthe bacteriophage SP6. Both of these RNA polymerases are highly specificand require the insertion of bacteriophage-specific sequences at the 5'end of the message to be read. See, J. Sambrook, et al., supra, at18.82-18.84.

This invention also provides nucleic acids, RNA or DNA, which arecomplementary to SEQ ID NO:1 or SEQ ID NO:3.

The present invention also provides probes and primers useful formolecular biology techniques. A compound which encodes for SEQ ID NO:1,SEQ ID NO:3 or a complementary sequence of SEQ ID NO:1 or SEQ ID NO:3,or a fragment thereof, and which is at least 18 base pairs in length,and which will selectively hybridize to human genomic DNA or messengerRNA encoding a human brain Na⁺ -dependent inorganic phosphatecotransporter, is provided. Preferably, the 18 or more base paircompound is DNA.

The term "selectively hybridize" as used herein may refer to either oftwo situations. In the first such embodiment of this invention, thenucleic acid compounds described supra hybridize to a humansodium-dependent inorganic phosphate cotransporter under more stringenthybridization conditions than these same nucleic acid compounds wouldhybridize to an analogous sodium-dependent inorganic phosphatecotransporter of another species, e.g. murine or primate. In the secondsuch embodiment of this invention, these probes hybridize to the hBNPIprotein of the present invention under more stringent hybridizationconditions than other related compounds, including nucleic acidsequences encoding other ion cotransporters.

These probes and primers can be prepared enzymatically as describedsupra. In a most preferred embodiment these probes and primers aresynthesized using chemical means as described supra. Probes and primersof defined structure may also be purchased commercially.

This invention also encompasses recombinant DNA cloning vectors andexpression vectors comprising the nucleic acids of the presentinvention. Many of the vectors encompassed within this invention aredescribed above. The preferred nucleic acid vectors are those which areDNA.

The sequence of SEQ ID NO:1 was prepared as follows:

Molecular cloning of a human brain Na⁺ -dependent inorganic phosphatecotransporter(hBNPI)

Using a cDNA encoding the rat brain Na⁺ -dependent inorganic phosphatecotransporter (rBNPI)(Ni, et al., 1994), we screened, under lowstringency conditions, a human cDNA library derived from hippocampusmRNAs. Twelve positive clones were isolated that strongly hybridized tothe ³² P-labeled probe rBNPI. Restriction endonuclease analysis and/orsequencing of these clones revealed two distinct sequences: those whichare highly similar to the rBNPI (B. Ni, et al., 1994, supra) as well asthe kidney Na⁺ -dependent inorganic phosphate cotransporter (Na/P_(i)),found in 10 clones, and those found in 2 clones which were proved to berearrangments between the human putative phosphate transporter and othercDNAs. Of the 10 clones (designed as hBNP) which exhibited a strongsimilarity to rBNPI, 4 clones contained the 2.7 kb message. Sequenceanalysis of hBNPI predicts an open reading frame of 1683 bases,corresponding to a protein of 560 amino acids with an apparent molecularmass of 61,000 Da (61 kDa). The ATG initiation codon at position 1,which is preceded by an upstream, in-frame stop codon, matches the Kazakconsensus initiation sequence for the initiation of translation.

Computer searching revealed that the protein encoded by the hBNPI sharedsignificant sequence homology at the amino acid level with those ofrecently cloned rat rBNPI (98%), rabbit (31%) and human (31%) kidneyphosphate transporter, Na/P_(i), as indicated by comparison analysis.The highest degree of homology, which was found between rBNPI and hBNPI,suggested that hBNPI is the human homologue of the rat rBNPI. Thesegment of highest homology among the proteins is confined to a regionthat fits the proposed consensus Na⁺ -binding domain for various Na⁺-dependent transporter systems (Deguchi et al., 1990). Alignment of thepredicted hBNPI protein sequence with the consensus sequence indicatedthat amino acids leucine (L), glycine (G) and arginine (R) residuesmatch the proposed motif and that other (F and R) are conservativelychanged. The predicted hBNPI protein sequence also shares 41% and 32%amino acid identity with two proteins of unknown function fromCaenorhabditis elegans, ZK512.6 and C38C10.2, respectively. J. Sulstonet al., Nature (London), 356:37-41 (1992). A hydropathy plot of thededuced amino acid sequence of hBNPI suggests the presence of at least 6to 8 transmembrane regions. This number of membrane-spanning domains isa characteristic structural motif of transport proteins. Based on theconvention that activity of neuronal P_(i) transport correlates with ATPsynthesis and intracellular energy charge, we have modelled hBNPIprotein secondary structure with 6 transmembrane domains, which isconsistent with those of other energy-linked anion transporters. Theputative two glycosylation sites and two protein kinase Cphosphorylation sites and four putative calmodulin-dependent kinase IIphosphorylation sites are well conserved.

The skilled artisan understands that the type of cloning vector orexpression vector employed depends upon the availability of appropriaterestriction sites, the type of host cell in which the vector is to betransfected or transformed, the purpose of the transfection ortransformation (e.g., transient expression in an oocyte system, stabletransformation as an extrachromosomal element, or integration into thehost chromosome), the presence or absence of readily assayable markers(e.g., antibiotic resistance markers, metabolic markers, or the like),and the number of copies of the gene to be present in the cell.

The type of vector employed to carry the nucleic acids of the presentinvention may be RNA viruses, DNA viruses, lyric bacteriophages,lysogenic bacteriophages, stable bacteriophages, plasmids, viroids, andthe like. The most preferred vectors of the present invention are thosederived from plasmids.

When preparing an expression vector the skilled artisan understands thatthere are many variables to be considered. One such example is the useof a constitutive promoter, i.e. a promoter which is functional at alltimes, instead of a regularable promoter which may be activated orinactivated by the artisan using heat, addition or removal of anutrient, addition of an antibiotic, and the like. The practitioner alsounderstands that the amount of nucleic acid or protein to be produceddictates, in part, the selection of the expression system. Forexperiments examining the amount of the protein expressed on the cellmembrane or for experiments examining the biological function of anexpressed membrane protein, for example, it may be unwise to employ anexpression system which produces too much of the protein. The additionor subtraction of certain sequences, such as a signal sequence precedingthe coding sequence, may be employed by the practitioner to influencelocalization of the resulting polypeptide. Such sequences added to orremoved from the nucleic acid compounds of the present invention areencompassed within this invention.

The starting plasmids employed to prepare the vectors of the presentinvention may be isolated from the appropriate E. coli containing theseplasmids using standard procedures such as cesium chloride DNAisolation.

The plasmids of the present invention may be readily modified toconstruct expression vectors that produce hBNPI proteins in a variety oforganisms, including, for example, E. coli Sf9 (as host forbaculovirus), Spodoptera and Saccharomyces. The current literaturecontains techniques for constructing AV12 expression vectors and fortransforming AV12 host cells. U.S. Pat. No. 4,992,373, hereinincorporated by reference, is one of many references describing thesetechniques.

One of the most widely employed techniques for altering a nucleic acidsequence is by way of oligonucleotide-directed site-specificmutagenesis. B. Comack, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY,8.01-8.5.9, (F. Ausubel, et al., eds. 1991). In this technique anoligonucleotide, whose sequence contains the mutation of interest, issynthesized as described supra. This oligonucleotide is then hybridizedto a template containing the wild-type sequence. In a most preferredembodiment of this technique, the template is a single-strandedtemplate. Particularly preferred are plasmids which contain regions suchas the f1 intergenic region. This region allows the generation ofsingle-stranded templates when a helper phage is added to the cultureharboring the "phagemid".

After the annealing of the oligonucleotide to the template, aDNA-dependent DNA polymerase is then used to synthesize the secondstrand from the oliognucleotide, complementary to the template DNA. Theresulting product is a heteroduplex molecule containing a mismatch dueto the mutation in the oligonucleotide. After DNA replication by thehost cell a mixture of two types of plasmid are present, the wild-typeand the newly constructed mutant. This technique permits theintroduction of convenient restriction sites such that the codingsequence may be placed immediately adjacent to whichever transcriptionalor translational regulatory elements are employed by the practitioner.

The construction protocols utilized for E. coli can be followed toconstruct analogous vectors for other organisms, merely by substituting,if necessary, the appropriate regulatory elements using techniques wellknown to skilled artisans.

Host cells which harbor the nucleic acids provided by the presentinvention are also provided. A preferred host cell is an Xenopus sp.oocyte which has been injected with RNA or DNA compounds of the presentinvention. Most preferred oocytes of the present invention are thosewhich harbor a sense mRNA of the present invention. Other preferred hostcells include AV12 and E. coli cells which have been transfected and/ortransformed with a vector which comprises a nucleic acid of the presentinvention.

The present invention also provides a method for constructing arecombinant host cell capable of expressing SEQ ID NO:2, said methodcomprising transforming a host cell with a recombinant DNA vector thatcomprises an isolated DNA sequence which encodes SEQ ID NO:2. Thepreferred host cell is AV12. The preferred vector for expression is onewhich comprises SEQ ID NO:1. Another preferred host cell for this methodis E. coli. An especially preferred expression vector in E. coli is onewhich comprises SEQ ID NO:1. Transformed host cells may be culturedunder conditions well known to skilled artisans such that SEQ ID NO:2 isexpressed, thereby producing Yb in the recombinant host cell.

The ability of ions to bind to the hBNPI protein is essential in thedevelopment of a multitude of indications. In developing agents whichact as antagonists or agonists of the hBNPI protein, it would bedesirable, therefore, to determine those agents which bind the hBNPIprotein. Generally, such an assay includes a method for determiningwhether a substance is a functional ligand of the hBNPI protein, saidmethod comprising contacting a functional compound of the hBNPI proteinwith said substance, monitoring binding activity by physicallydetectable means, and identifying those substances which effect a chosenresponse. Preferably, the physically detectable means is competitionwith labeled inorganic phosphate or binding of ligand in an oocytetransient expression system

The instant invention provides such a screening system useful fordiscovering agents which compete with inorganic phosphate for binding tothe hBNPI protein, said screening system comprising the seeps of:

a) isolating a human hBNPI protein;

b) exposing said human hBNPI protein to a potential inhibitor orsurrogate of the P_(i) /hBNPI protein complex;

c) introducing P_(i) ;

d) removing non-specifically bound molecules; and

e) quantifying the concentration of bound potential inhibitor and/orP_(i).

This allows one to rapidly screen for inhibitors or surrogates of theformation of the P_(i) /hBNPI protein complex. Utilization of thescreening system described above provides a sensitive and rapid means todetermine compounds which interfere with the formation of the P_(i)/hBNPI protein complex. This screening system may also be adapted toautomated procedures such as a PANDEX® (Baxter-Dade Diagnostics) systemallowing for efficient high-volume screening of potential therapeuticagents.

In such a screening protocol a hBNPI protein is prepared as elsewheredescribed herein, preferably using recombinant DNA technology. A sampleof a test compound is then introduced to the reaction vessel containingthe hBNPI protein followed by the addition of P_(i). In the alternativethe P_(i) may be added simultaneously with the test compound. Unboundmolecules are washed free and the eluent inspected for the presence ofP_(i) or the test compound.

For example, in a preferred method of the invention, radioactivelylabeled P_(i) may be used. The eluent is then scored for theradioactivity. The absence or diminution of the chemical label orradioactivity indicates the formation of the P_(i) /hBNPI proteincomplex. This indicates that the test compound has not effectivelycompeted with P_(i) in the formation of the P_(i) /hBNPI proteincomplex. The presence of the chemical label or radioactivity indicatesthat the test compound has competed with P_(i) in the formation of theP_(i) /hBNPI protein complex. Similarly, a radioactively or chemicallylabeled test compound may be used in which case the same steps asoutlined above would be used except that the interpretation of resultswould be the converse of using radioactively labelled P_(i).

As would be understood by the skilled artisan these assays may also beperformed such that the practitioner measures the radioactivityremaining with the protein, not in the eluent. A preferred such assayemploys radiolabeled P_(i). After the competition reaction has beenperformed the reaction mixture is then passed through a filter, thefilter retaining the receptor and whatever is complexed with thereceptor. The radioactivity on each filter is then measured in ascintillation counter. In such an assay higher amounts of radiolabelpresent indicate lower affinity for the receptor by the test compound.

The hBNPI protein may be free in solution or bound to a solid support.Whether the hBNPI protein is bound to a support or is free in solution,it is generally important that the conformation of the protein beconserved. In a preferred practice of the invention, therefore, thehBNPI protein is suspended in a hydrophobic environment employingnatural or synthetic detergents, membrane suspensions, and the like.Preferred detergent complexes include the zwitterionic detergent3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonate ("CHAPS") aswell as sodium deoxycholate.

Skilled artisans will recognize that desirable dissociation constant(K_(i)) values are dependent on the selectivity of the compound tested.For example, a compound with a K_(i) which is less than 10 nM isgenerally considered an excellent candidate for drug therapy. However, acompound which has a lower affinity, but is selective for the particularreceptor, may be an even better candidate. The present invention,however, provides radiolabeled competition assays, whether resultstherefrom indicate high affinity or low affinity to hBNPI protein,because skilled artisans will recognize that any information regardingbinding or selectivity of a particular compound is beneficial in thepharmaceutical development of drugs.

Assays useful for evaluating ion channel cotransporters are well knownin the art. See, e.g., B. Ni, et al., supra. One such assay is describedbelow.

Functional analysis of hBNPI in transfected COS-1 cells

To confirm the functional properties of the hBNPI protein, weconstructed the hBNPI cDNA into a mammalian expression vector (pcDNA3)and transfected the pcDNA3-hBNPI constructs into the COS-1 cells.Sodium-dependent ³² Pi uptake in the cells transfected with hBNPI wasstimulated 2-3 fold above that of those transfected with vectors aloneor of nontransfected cells. Replacement of sodium chloride with cholinechloride reduced ³² Pi uptake to background levels. Northern blotanalysis was employed to examine the expression of hBNPI gene intransfected COS-1 cell lines. Labeled hBNPI cDNA detected strongexpression of hBNPI transcripts in the COS-1 cells transfected withhBNPI but not in those cells transfected with the vector alone.

Expression of hBNPI mRNA in human brain

We examined hBNPI expression in multiple human tissues by probingpolyadenylated RNA from heart, brain, placenta, lung, liver, skeletalmuscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, smallintestine, colon and peripheral blood leukocytes. The Northern blotanalysis demonstrated that hBNPI probe detected a single mRNA species of2.8 kb and strong expression of hBNPI transcript in the brain tissue.Trace levels of the hBNPI could be detected in RNA fractions from thesmall intestine, colon and testis if the blot was overexposured for alonger period of time (five days versus the usual one day exposure). Nosignal could be detected in the other tissues. The level of hBNPI in thebrain fraction is at least 100 times higher than that in the intestineor colon. Northern blot analysis with multiple human brain regions showsthat hBNPI mRNA is expressed in specific brain regions: most abundantlyin neuron-enriched areas such as the amygdala and hippocampus; atmoderate levels in glia-enriched areas such as the corpus callosum; andat low levels in the substantia niga, subthalamic nuclei and thalamus.No hBNPI transcript was detected in RNAs isolated from the caudatenucleus and hypothalamus.

A Northern blot of human brain mRNA isolated from fetal and adult (37yr-old) brain was prepared for the characterization of expression of thehBNPI during brain development. The blot was hybridized with ³²P-labeled hBNPI cDNA and human β-actin cDNA. The relative abundance ofhBNPI mRNA shows a dramatic increase during postnatal development.

In situ hybridization histochemistry was employed to examine cells whichexpress hBNPI transcripts in the human brain. hBNPI mRNA is highlyexpressed in the hippocampus formation and cerebral cortex. While thehybridization signal is present in various layers of the cerebralcortex, it appears to be more abundant in the neuronal layer v-vi wherea distinct labeling is observed of pyramidal and non-pyramidal neurons.On closer inspection, it is apparent that hBNPI transcripts areconcentrated in the pyramidal neurons of hippocampus and granule neuronsof dentate gyrus. The hybridization signal was also detected inglia-enriched areas such as the corpus callosum, a finding which isconsistent with data observed in Northern blot analysis of hBNPI mRNA inthe human brain, and which suggests that, unlike its rat counterpartrBNPI, the hBNPI mRNA is expressed not only in neurons but also in gliaas well. Cf., Ni, et al., supra.

Genomic analysis Of the hBNPI gene

Genomic Southern blotting is a valuable tool for identifying homologousgenes in various species. We used hBNPI cDNA to detect hBNPI genes in avariety of vertebrate species under stringent hybridization condition.The species tested included human, monkey, rat, mouse, dog, cow, rabbit,chicken and yeast. One major fragment which appears to harbor hBNPI genewas detected in the human, monkey, dog, cow and rabbit. Two fragmentsgenerated by internal EcoRI sites were detected in the rat and mouse. Nosignal was detected in yeast DNA. The results suggest that hBNPIsequence is well conserved among vertebrate species.

Genomic DNAs derived from four human individuals were digested withrestriction endonuclases and used to determine the hBNPI gene structureand possible polymorphisms by Southern blot techniqus utilizing the fulllength hBNPI cDNA as a probe. The restriction patterns derived from 9restrictions endonuclases are rather simple, and are similar between thefour individuals. One major hybridizing fragment is generated byinternal EcoRI, BglII, HindIII, PstI, PvuII, respectively. One majorfragment with multiple weak hybridizing bands was generated by internaldigestion with TaqI, MspI and BamHI. The results suggest that hBNPI genestructure is compact, that it is most likely present as a single copy,and that no polymorphisms of hBNPI gene exist.

Chromosome localization

Using hBNPI cDNA we screened a library constructed with human leukocyteDNA to isolate the hBNPI gene. After several rounds of screening, a 23kb DNA fragment was isolated and identified as hBNPI gene. The hBNPIgene was labeled with digoxigenin dUTP by nick translation andhybridized to normal metaphase chromosomes derived from PHA-stimulatedperipheral blood lymphocytes using a fluorescent in situ hybridization(FISH) technique. A specific hybridization signal was detected in thelong arm of chromosome 19. Assignment of the hBNPI gene to the region of19 was further confirmed by colocalization of a chromosome 19 specificprobe, E2A, with the hBNPI gene. Measurements of ten specificallyhybridized chromosomes 19 demonstrated that hBNPI gene is located 66% ofthe distance from the centromere to the telomere of chromosome arm 19q,an area that corresponds to band 19q13.3. No positive signals wereobserved in any other chromosomes. Analysis of interphase cells showonly one copy of the probe present in the human genome, a finding whichis consistent with the results of the genomic Southern blot.

The previously described screening systems identify compounds whichcompetitively bind to the hBNPI protein. Determination of the ability ofsuch compounds to stimulate or inhibit the action of the hBNPI proteinis essential to further development of such compounds for therapeuticapplications. The need for a bioactivity assay system which determinesthe response of the hBNPI protein to a compound is clear. The instantinvention provides such a bioactivity assay, said assay comprising thesteps of:

a) transfecting a mammalian host cell with an expression vectorcomprising DNA encoding a hBNPI protein;

b) culturing said host cell under conditions such that the DNA encodingthe hBNPI protein is expressed,

c) exposing said host cell so transfected to a test compound, and

d) measuring the change in a physiological condition known to beinfluenced by the binding of a cation to the hBNPI protein relative to acontrol in which the transfected host cell is not exposed to the testcompound.

An oocyte transient expression system can be constructed according tothe procedure described in S. Lubbert, et al., Proceedings of theNational Academy of Sciences (U.S.A.), 84:4332 (1987).

In an especially preferred embodiment of this invention an assaymeasuring the inhibition of radiolabeled phosphate uptake was performed.The inhibition of phosphate uptake is a relatively simple assay used todetermine thsoe agents which negatively affect the proteins of thepresent invention.

In another embodiment this invention provides a method for identifying,in a test sample, DNA homologous to a probe of the present invention,wherein the test nucleic acid is contacted with the probe underhybridizing conditions and identified as being homologous to the probe.Hybridization techniques are well known in the art. See, e.g., J.Sambrook, et al., supra, at Chapter 11.

The nucleic acid compounds of the present invention may also be used tohybridize to genomic DNA which has been digested with one or morerestriction enzymes and run on an electrophoretic gel. The hybridizationof radiolabeled probes onto such restricted DNA, usually fixed to amembrane after electrophoresis, is well known in the art. See, e.g., J.Sambrook, supra. Such procedures may be employed in searching forpersons with mutations in these receptors by the well-known techniquesof restriction fragment length polymorphisms (RFLP), the procedures ofwhich are described in U.S. Pat. No. 4,666,828, issued May 19, 1987, theentire contents of which is herein incorporated by reference.

The proteins of this invention as well as fragments of these proteinsmay be used as antigens for the synthesis of antibodies. The term"antibody" as used herein describes antibodies, fragments of antibodies(such as, but not limited, to Fab, Fab', Fab₂ ', and Fv fragments), andchimeric, humanized, veneered, resurfaced, or CDR-grafted antibodiescapable of binding antigens of a similar nature as the parent antibodymolecule from which they are derived. The instant invention alsoencompasses single chain polypeptide binding molecules.

The term "antibody" as used herein is not limited by the manner in whichthe antibodies are produced, whether such production is in situ or not.The term "antibody" as used in this specification encompasses thoseantibodies produced by recombinant DNA technology means including, butnot limited, to expression in bacteria, yeast, insect cell lines, ormammalian cell lines.

The production of antibodies, both monoclonal and polyclonal, inanimals, especially mice, is well known in the art. See, e.g., C.Milstein, HANDBOOK OF EXPERIMENTAL IMMUNOLOGY, (Blackwell ScientificPub., 1986); J. Goding, Monoclonal Antibodies: Principles and Practice,(Academic Press, 1983). For the production of monoclonal antibodies thebasic process begins with injecting a mouse, or other suitable animal,with an immunogen. The mouse is subsequently sacrificed and cells takenfrom its spleen are fused with myeloma cells, resulting in a hybridomathat reproduces in vitro. The population of hybridomas is screened toisolate individual clones, each of which secretes a single antibodyspecies, specific for the immunogen. The individual antibody speciesobtained in this way is each the product of a single B cell from theimmune animal generated in response to a specific antigenic site, orepitope, recognized on the immunogenic substance.

Chimeric antibodies are described in U.S. Pat. No. 4,816,567, whichissued Mar. 28, 1989 to S. Cabilly, et al. This reference disclosesmethods and vectors for the preparation of chimeric antibodies. Theentire contents of U.S. Pat. No. 4,816,567 are herein incorporated byreference. An alternative approach to production of geneticallyengineered antibodies is provided in U.S. Pat. No. 4,816,397, which alsoissued Mar. 28, 1989 to M. Boss, et al., the entire contents of whichare herein incorporated by reference. The Boss patent teaches thesimultaneous coexpression of the heavy and light chains of the antibodyin the same host cell.

The approach of U.S. Pat. No. 4,816,397 has been further refined astaught in European Patent Publication No. 239 400, which published Sep.30, 1987. The teachings of this European patent publication (Winter) area preferred format for the genetic engineering of the reactivemonoclonal antibodies of this invention. The Winter technology involvesthe replacement of complementarity determining regions (CDRs) of a humanantibody with the CDRs of a murine monoclonal antibody therebyconverting the specificity of the human antibody to the specificity ofthe murine antibody which was the source of the CDR regions. This "CDRgrafting" technology affords a molecule containing minimal murinesequence and thus is less immunogenic.

Single chain antibody technology is yet another variety of geneticallyengineered antibody which is now well known in the art. See, e.g, R. E.Bird, et al., Science 242:423-426 (1988); Patent cooperation TreatyPublication No. WO 88/01649, which was published 10 March 1988. Thesingle chain antibody technology involves joining the binding regions ofheavy and light chains with a polypeptide sequence to generate a singlepolypeptide having the binding specificity of the antibody from which itwas derived.

The aforementioned genetic engineering approaches provide the skilledartisan with numerous means to generate molecules which retain thebinding characteristics of the parental antibody while affording a lessimmunogenic format.

These antibodies are used in diagnostics, therapeutics or indiagnostic/therapeutic combinations. By "diagnostics" as used herein ismeant testing that is related to either the in vitro or in vivodiagnosis of disease states or biological status in mammals, preferablyin humans. By "therapeutics" and "therapeutic/diagnostic combinations"as used herein is respectively meant the treatment or the diagnosis andtreatment of disease states or biological status by the in vivoadministration to mammals, preferably humans, of the antibodies of thepresent invention. The antibodies of the present invention areespecially preferred in the diagnosis and/or treatment of conditionsassociated with an excess or deficiency of hBNPI proteins.

In addition to being functional as direct therapeutic and diagnosticaids, the availability of a family of antibodies which are specific forthe hBNPI protein enables the development of numerous assay systems fordetecting agents which bind to this protein. One such assay systemcomprises radiolabeling hBNPI protein-specific antibodies with aradionuclide such as ¹²⁵ I and measuring displacement of theradiolabeled hBNPI protein-specific antibody from solid phase hBNPIprotein in the presence of a potential antagonist or inhibitor.

Numerous other assay systems are also readily adaptable to detect agentswhich bind hBNPI protein. Examples of these aforementioned assay systemsare discussed in Methods in Enzymology, (J. Langone. and H. Vunakis,ads. 1981), Vol. 73, Part B, the contents of which are hereinincorporated by reference. Skilled artisans are directed to Section IIof Methods in Enzymology, Vol. 73, Part B, supra, which discusseslabeling of antibodies and antigens, and Section IV, which discussesimmunoassay methods.

In addition to the aforementioned antibodies specific for the hBNPIprotein, this invention also provides antibodies which are specific forthe hypervariable regions of the anti-hBNPI protein antibodies. Somesuch anti-idiotypic antibodies would resemble the original epitope, thehBNPI protein, and, therefore, would be useful in evaluating theeffectiveness of compounds which are potential antagonists, agonists, orpartial agonists of the hBNPI protein. See, e.g., Cleveland, et al.,Nature (London), 305:56 (1983); Wasserman, et al., Proceedings of theNational Academy of Sciences (U.S.A.), 79:4810 (1982).

In another embodiment, this invention encompasses pharmaceuticalformulations for parenteral administration which contain, as the activeingredient, the anti-hBNPI protein antibodies described, supra. Suchformulations are prepared by methods commonly used in pharmaceuticalchemistry.

Products for parenteral administration are often formulated anddistributed in solid, preferably freeze-dried form, for reconstitutionimmediately before use. Such formulations are useful compositions of thepresent invention. Their preparation is well understood bypharmaceutical chemists.

In general, these formulations comprise the active ingredient incombination with a mixture of inorganic salts, to confer isotonicity, aswell as dispersing agents such as lactose, to allow the driedpreparation to dissolve quickly upon reconstitution. Such formulationsare reconstituted for use with highly purified water to a knownconcentration.

Alternatively, a water soluble form of the antibody can be dissolved inone of the commonly used intravenous fluids and administered byinfusion. Such fluids include physiological saline, Ringer's solution ora 5% dextrose solution.

    __________________________________________________________________________    SEQUENCE LISTING                                                              (1) GENERAL INFORMATION:                                                      (iii) NUMBER OF SEQUENCES: 3                                                  (2) INFORMATION FOR SEQ ID NO:1:                                              (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 2716 base pairs                                                   (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                          (ii) MOLECULE TYPE: cDNA                                                      (ix) FEATURE:                                                                 (A) NAME/KEY: CDS                                                             (B) LOCATION: 461..2140                                                       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                                       CGATAAGCTTGATATCGAATTCCGGACTCTTGCTCGGGCGCCTTAACCCGGCGTTCGGTT60                CATCCCGCAGCGCCAGTTCTGCTTACCAAAAGTGGCCCACTAGGCACTCGCATTCCACGC120               CCGGCTCCACGCCAGCGAGCCGGGCTTCTTACCCATTTAAAGTTTGAGAATAGGTTGAGA180               TCGTTTCGGCCCCAAGACCTCTAATCATTCGCTTTACCGGATAAAACTGCGTGGCGGGGG240               TGCGTCGGGTCTGCGAGAGCGCCAGCTATCCTGAGGGAAACTTCGGAGGGAACCAGCTAC300               TAGATGGTTCGATTAGTCTTTCGCCCCTATACCCAGGTCGGACGACCGATTTGCACGTCA360               GGACCGCTACGGACCTCCACCAGAGTTTCCTCTGGCTTCGCCCTGCCCAGGCGATCGGCG420               GGGGGGACCCGCGGGGTGACCGGCGGCAGGAGCCGCCACCATGGAGTTCCGCCAG475                    MetGluPheArgGln                                                               15                                                                            GAGGAGTTTCGGAAGCTAGCGGGTCGTGCTCTCGGGAAGCTGCACCGC523                           GluGluPheArgLysLeuAlaGlyArgAlaLeuGlyLysLeuHisArg                              101520                                                                        CTTCTGGAGAAGCGGCAGGAAGGCGCGGAGACGCTGGAGCTGAGTGCG571                           LeuLeuGluLysArgGlnGluGlyAlaGluThrLeuGluLeuSerAla                              253035                                                                        GATGGGCGCCCGGTGACCACGCAGACCCGGGACCCGCCGGTGGTGGAC619                           AspGlyArgProValThrThrGlnThrArgAspProProValValAsp                              404550                                                                        TGCACCTGCTTCGGCCTCCCTCGCCGCTACATTATCGCCATCATGAGT667                           CysThrCysPheGlyLeuProArgArgTyrIleIleAlaIleMetSer                              556065                                                                        GGTCTGGGCTTCTGCATCAGCTTTGGCATCCGCTGCAACCTGGGCGTG715                           GlyLeuGlyPheCysIleSerPheGlyIleArgCysAsnLeuGlyVal                              70758085                                                                      GCCATCGTCTCCATGGTCAATAACAGCACGACCCACCGCGGGGGCCAC763                           AlaIleValSerMetValAsnAsnSerThrThrHisArgGlyGlyHis                              9095100                                                                       GTGGTGGTGCAGAAAGCCCAGTTCAGCTGGGATCCAGAGACTGTCGGC811                           ValValValGlnLysAlaGlnPheSerTrpAspProGluThrValGly                              105110115                                                                     CTCATACACGGCTCCTTTTTCTGGGGCTACATTGTCACTCAGATTCCA859                           LeuIleHisGlySerPhePheTrpGlyTyrIleValThrGlnIlePro                              120125130                                                                     GGAGGATTTATCTGTCAAAAATTTGCAGCCAACAGAGTTTTCGGCTTT907                           GlyGlyPheIleCysGlnLysPheAlaAlaAsnArgValPheGlyPhe                              135140145                                                                     GCTATTGTGGCAACATCCACTCTAAACATGCTGATCCCCTCAGCTGCC955                           AlaIleValAlaThrSerThrLeuAsnMetLeuIleProSerAlaAla                              150155160165                                                                  CGCGTCCACTATGGCTGTGTCATCTTCGTGAGGATCCTGCAGGGGTTG1003                          ArgValHisTyrGlyCysValIlePheValArgIleLeuGlnGlyLeu                              170175180                                                                     GTAGAGGGGGTCACATACCCCGCCTGCCATGGGATCTGGAGCAAATGG1051                          ValGluGlyValThrTyrProAlaCysHisGlyIleTrpSerLysTrp                              185190195                                                                     GCCCCACCCTTAGAACGGAGTCGCCTGGCGACGACAGCCTTTTGTGGT1099                          AlaProProLeuGluArgSerArgLeuAlaThrThrAlaPheCysGly                              200205210                                                                     TCCTATGCTGGGGCGGTGGTCGCGATGCCCCTCGCCGGGGTCCTTGTG1147                          SerTyrAlaGlyAlaValValAlaMetProLeuAlaGlyValLeuVal                              215220225                                                                     CAGTACTCAGGATGGAGCTCTGTTTTCTACGTCTACGGCAGCTTCGGG1195                          GlnTyrSerGlyTrpSerSerValPheTyrValTyrGlySerPheGly                              230235240245                                                                  ATCTTCTGGTACCTGTTCTGGCTGCTCGTCTCCTACGAGTCCCCCGCG1243                          IlePheTrpTyrLeuPheTrpLeuLeuValSerTyrGluSerProAla                              250255260                                                                     CTGCACCCCAGCATCTCGGAGGAGGAGCGCAAGTACATCGAGGACGCC1291                          LeuHisProSerIleSerGluGluGluArgLysTyrIleGluAspAla                              265270275                                                                     ATCGGAGAGAGCGCGAAACTCATGAACCCCCTCACGAAGTTTAGCACT1339                          IleGlyGluSerAlaLysLeuMetAsnProLeuThrLysPheSerThr                              280285290                                                                     CCCTGGCGGCGCTTCTTCACGTCTATGCCAGTCTATGCCATCATCGTG1387                          ProTrpArgArgPhePheThrSerMetProValTyrAlaIleIleVal                              295300305                                                                     GCCAACTTCTGCCGCAGCTGGACGTTCTACCTGCTGCTCATCTCCCAG1435                          AlaAsnPheCysArgSerTrpThrPheTyrLeuLeuLeuIleSerGln                              310315320325                                                                  CCCGACTACTTCGAAGAAGTGTTCGGCTTCGAGATCAGCAAGGTAGGC1483                          ProAspTyrPheGluGluValPheGlyPheGluIleSerLysValGly                              330335340                                                                     CTGGTGTCCGCGCTGCCCCACCTGGTCATGACCATCATCGTGCCCATC1531                          LeuValSerAlaLeuProHisLeuValMetThrIleIleValProIle                              345350355                                                                     GGCGGCCAGATCGCGGACTTCCTGCGGAGCCGCCGCATCATGTCCACC1579                          GlyGlyGlnIleAlaAspPheLeuArgSerArgArgIleMetSerThr                              360365370                                                                     ACCAACGTGCGCAAGTTGATGAACTGCGGAGGCTTCGGCATGGAAGCC1627                          ThrAsnValArgLysLeuMetAsnCysGlyGlyPheGlyMetGluAla                              375380385                                                                     ACGCTGCTGTTGGTGGTCGGCTACTCGCACTCCAAGGGCGTGGCCATC1675                          ThrLeuLeuLeuValValGlyTyrSerHisSerLysGlyValAlaIle                              390395400405                                                                  TCCTTCCTGGTCCTAGCCGTGGGCTTCAGCGGCTTCGCCATCTCTGGG1723                          SerPheLeuValLeuAlaValGlyPheSerGlyPheAlaIleSerGly                              410415420                                                                     TTCAACGTGAACCACCTGGACATAGCCCCGCGCTACGCCAGCATCCTC1771                          PheAsnValAsnHisLeuAspIleAlaProArgTyrAlaSerIleLeu                              425430435                                                                     ATGGGCATCTCCAACGGCGTGGGCACACTGTCGGGCATGGTGTGCCCC1819                          MetGlyIleSerAsnGlyValGlyThrLeuSerGlyMetValCysPro                              440445450                                                                     ATCATCGTGGGGGCCATGACTAAGCACAAGACTCGGGAGGAGTGGCAG1867                          IleIleValGlyAlaMetThrLysHisLysThrArgGluGluTrpGln                              455460465                                                                     TACGTGTTCCTAATTGCCTCCCTGGTGCACTATGGAGGTGTCATCTTC1915                          TyrValPheLeuIleAlaSerLeuValHisTyrGlyGlyValIlePhe                              470475480485                                                                  TACGGGGTCTTTGCTTCTGGAGAGAAGCAGCCGTGGGCAGAGCCTGAG1963                          TyrGlyValPheAlaSerGlyGluLysGlnProTrpAlaGluProGlu                              490495500                                                                     GAGATGAGCGAGGAGAAGTGTGGCTTCGTTGGCCATGACCAGCTGGCT2011                          GluMetSerGluGluLysCysGlyPheValGlyHisAspGlnLeuAla                              505510515                                                                     GGCAGTGACGACAGCGAAATGGAGGATGAGGCTGAGCCCCCGGGGGCA2059                          GlySerAspAspSerGluMetGluAspGluAlaGluProProGlyAla                              520525530                                                                     CCCCCTGCACCCCCGCCCTCCTATGGGGCCACACACAGCACATTTCAG2107                          ProProAlaProProProSerTyrGlyAlaThrHisSerThrPheGln                              535540545                                                                     CCCCCCAGGCCCCCACCCCCTGTCCGGGACTACTGACCATGTGCCTCCCACTG2160                     ProProArgProProProProValArgAspTyr                                             550555560                                                                     AATGGCAGTTTCCAGGACCTCCATTCCACTCATCTCTGGCCTGAGTGACAGTGTCAAGGA2220              ACCCTGCTCCTCTCTGTCCTGCCTCAGGCCTAAGAAGCACTCTCCCTTGTTCCCAGTGCT2280              GTCAAATCCTCTTTCCTTCCCAATTGCCTCTCAGGGGTAGTGAAGCTGCAGACTGACAGT2340              TTCAAGGATACCCAAATTCCCCTAAAGGTTCCCTCTCCACCCGTTCTGCCTCAGTGGTTT2400              CAAATCTCTCCTTTCAGGGCTTTATTTGAATGGACAGTTCGACCTCTTACTCTCTCTTGT2460              GGTTTTGAGGCACCCACACCCCCCGCTTTCCTTTATCTCCAGGGACTCTCAGGCTAACCT2520              TTGAGATCACTCAGCTCCCATCTCCTTTCAGAAAAATTCAAGGTCCTCCTCTAGAAGTTT2580              CAAATCTCTCCCAACTCTGTTCTGCATCTTCCAGATTGGTTTAACCAATTACTCGTCCCC2640              GCCATTCCAGGGATTGATTCTCACCAGCGTTTCTGATGGAAAATGGCGGGAATTCCTGCA2700              GCCCGGGGGATCCACT2716                                                          (2) INFORMATION FOR SEQ ID NO:2:                                              (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 560 amino acids                                                   (B) TYPE: amino acid                                                          (D) TOPOLOGY: linear                                                          (ii) MOLECULE TYPE: protein                                                   (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                                       MetGluPheArgGlnGluGluPheArgLysLeuAlaGlyArgAlaLeu                              151015                                                                        GlyLysLeuHisArgLeuLeuGluLysArgGlnGluGlyAlaGluThr                              202530                                                                        LeuGluLeuSerAlaAspGlyArgProValThrThrGlnThrArgAsp                              354045                                                                        ProProValValAspCysThrCysPheGlyLeuProArgArgTyrIle                              505560                                                                        IleAlaIleMetSerGlyLeuGlyPheCysIleSerPheGlyIleArg                              65707580                                                                      CysAsnLeuGlyValAlaIleValSerMetValAsnAsnSerThrThr                              859095                                                                        HisArgGlyGlyHisValValValGlnLysAlaGlnPheSerTrpAsp                              100105110                                                                     ProGluThrValGlyLeuIleHisGlySerPhePheTrpGlyTyrIle                              115120125                                                                     ValThrGlnIleProGlyGlyPheIleCysGlnLysPheAlaAlaAsn                              130135140                                                                     ArgValPheGlyPheAlaIleValAlaThrSerThrLeuAsnMetLeu                              145150155160                                                                  IleProSerAlaAlaArgValHisTyrGlyCysValIlePheValArg                              165170175                                                                     IleLeuGlnGlyLeuValGluGlyValThrTyrProAlaCysHisGly                              180185190                                                                     IleTrpSerLysTrpAlaProProLeuGluArgSerArgLeuAlaThr                              195200205                                                                     ThrAlaPheCysGlySerTyrAlaGlyAlaValValAlaMetProLeu                              210215220                                                                     AlaGlyValLeuValGlnTyrSerGlyTrpSerSerValPheTyrVal                              225230235240                                                                  TyrGlySerPheGlyIlePheTrpTyrLeuPheTrpLeuLeuValSer                              245250255                                                                     TyrGluSerProAlaLeuHisProSerIleSerGluGluGluArgLys                              260265270                                                                     TyrIleGluAspAlaIleGlyGluSerAlaLysLeuMetAsnProLeu                              275280285                                                                     ThrLysPheSerThrProTrpArgArgPhePheThrSerMetProVal                              290295300                                                                     TyrAlaIleIleValAlaAsnPheCysArgSerTrpThrPheTyrLeu                              305310315320                                                                  LeuLeuIleSerGlnProAspTyrPheGluGluValPheGlyPheGlu                              325330335                                                                     IleSerLysValGlyLeuValSerAlaLeuProHisLeuValMetThr                              340345350                                                                     IleIleValProIleGlyGlyGlnIleAlaAspPheLeuArgSerArg                              355360365                                                                     ArgIleMetSerThrThrAsnValArgLysLeuMetAsnCysGlyGly                              370375380                                                                     PheGlyMetGluAlaThrLeuLeuLeuValValGlyTyrSerHisSer                              385390395400                                                                  LysGlyValAlaIleSerPheLeuValLeuAlaValGlyPheSerGly                              405410415                                                                     PheAlaIleSerGlyPheAsnValAsnHisLeuAspIleAlaProArg                              420425430                                                                     TyrAlaSerIleLeuMetGlyIleSerAsnGlyValGlyThrLeuSer                              435440445                                                                     GlyMetValCysProIleIleValGlyAlaMetThrLysHisLysThr                              450455460                                                                     ArgGluGluTrpGlnTyrValPheLeuIleAlaSerLeuValHisTyr                              465470475480                                                                  GlyGlyValIlePheTyrGlyValPheAlaSerGlyGluLysGlnPro                              485490495                                                                     TrpAlaGluProGluGluMetSerGluGluLysCysGlyPheValGly                              500505510                                                                     HisAspGlnLeuAlaGlySerAspAspSerGluMetGluAspGluAla                              515520525                                                                     GluProProGlyAlaProProAlaProProProSerTyrGlyAlaThr                              530535540                                                                     HisSerThrPheGlnProProArgProProProProValArgAspTyr                              545550555560                                                                  (2) INFORMATION FOR SEQ ID NO:3:                                              (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 2716 base pairs                                                   (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                          (ii) MOLECULE TYPE: mRNA                                                      (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:                                       CGAUAAGCUUGAUAUCGAAUUCCGGACUCUUGCUCGGGCGCCUUAACCCGGCGUUCGGUU60                CAUCCCGCAGCGCCAGUUCUGCUUACCAAAAGUGGCCCACUAGGCACUCGCAUUCCACGC120               CCGGCUCCACGCCAGCGAGCCGGGCUUCUUACCCAUUUAAAGUUUGAGAAUAGGUUGAGA180               UCGUUUCGGCCCCAAGACCUCUAAUCAUUCGCUUUACCGGAUAAAACUGCGUGGCGGGGG240               UGCGUCGGGUCUGCGAGAGCGCCAGCUAUCCUGAGGGAAACUUCGGAGGGAACCAGCUAC300               UAGAUGGUUCGAUUAGUCUUUCGCCCCUAUACCCAGGUCGGACGACCGAUUUGCACGUCA360               GGACCGCUACGGACCUCCACCAGAGUUUCCUCUGGCUUCGCCCUGCCCAGGCGAUCGGCG420               GGGGGGACCCGCGGGGUGACCGGCGGCAGGAGCCGCCACCAUGGAGUUCCGCCAGGAGGA480               GUUUCGGAAGCUAGCGGGUCGUGCUCUCGGGAAGCUGCACCGCCUUCUGGAGAAGCGGCA540               GGAAGGCGCGGAGACGCUGGAGCUGAGUGCGGAUGGGCGCCCGGUGACCACGCAGACCCG600               GGACCCGCCGGUGGUGGACUGCACCUGCUUCGGCCUCCCUCGCCGCUACAUUAUCGCCAU660               CAUGAGUGGUCUGGGCUUCUGCAUCAGCUUUGGCAUCCGCUGCAACCUGGGCGUGGCCAU720               CGUCUCCAUGGUCAAUAACAGCACGACCCACCGCGGGGGCCACGUGGUGGUGCAGAAAGC780               CCAGUUCAGCUGGGAUCCAGAGACUGUCGGCCUCAUACACGGCUCCUUUUUCUGGGGCUA840               CAUUGUCACUCAGAUUCCAGGAGGAUUUAUCUGUCAAAAAUUUGCAGCCAACAGAGUUUU900               CGGCUUUGCUAUUGUGGCAACAUCCACUCUAAACAUGCUGAUCCCCUCAGCUGCCCGCGU960               CCACUAUGGCUGUGUCAUCUUCGUGAGGAUCCUGCAGGGGUUGGUAGAGGGGGUCACAUA1020              CCCCGCCUGCCAUGGGAUCUGGAGCAAAUGGGCCCCACCCUUAGAACGGAGUCGCCUGGC1080              GACGACAGCCUUUUGUGGUUCCUAUGCUGGGGCGGUGGUCGCGAUGCCCCUCGCCGGGGU1140              CCUUGUGCAGUACUCAGGAUGGAGCUCUGUUUUCUACGUCUACGGCAGCUUCGGGAUCUU1200              CUGGUACCUGUUCUGGCUGCUCGUCUCCUACGAGUCCCCCGCGCUGCACCCCAGCAUCUC1260              GGAGGAGGAGCGCAAGUACAUCGAGGACGCCAUCGGAGAGAGCGCGAAACUCAUGAACCC1320              CCUCACGAAGUUUAGCACUCCCUGGCGGCGCUUCUUCACGUCUAUGCCAGUCUAUGCCAU1380              CAUCGUGGCCAACUUCUGCCGCAGCUGGACGUUCUACCUGCUGCUCAUCUCCCAGCCCGA1440              CUACUUCGAAGAAGUGUUCGGCUUCGAGAUCAGCAAGGUAGGCCUGGUGUCCGCGCUGCC1500              CCACCUGGUCAUGACCAUCAUCGUGCCCAUCGGCGGCCAGAUCGCGGACUUCCUGCGGAG1560              CCGCCGCAUCAUGUCCACCACCAACGUGCGCAAGUUGAUGAACUGCGGAGGCUUCGGCAU1620              GGAAGCCACGCUGCUGUUGGUGGUCGGCUACUCGCACUCCAAGGGCGUGGCCAUCUCCUU1680              CCUGGUCCUAGCCGUGGGCUUCAGCGGCUUCGCCAUCUCUGGGUUCAACGUGAACCACCU1740              GGACAUAGCCCCGCGCUACGCCAGCAUCCUCAUGGGCAUCUCCAACGGCGUGGGCACACU1800              GUCGGGCAUGGUGUGCCCCAUCAUCGUGGGGGCCAUGACUAAGCACAAGACUCGGGAGGA1860              GUGGCAGUACGUGUUCCUAAUUGCCUCCCUGGUGCACUAUGGAGGUGUCAUCUUCUACGG1920              GGUCUUUGCUUCUGGAGAGAAGCAGCCGUGGGCAGAGCCUGAGGAGAUGAGCGAGGAGAA1980              GUGUGGCUUCGUUGGCCAUGACCAGCUGGCUGGCAGUGACGACAGCGAAAUGGAGGAUGA2040              GGCUGAGCCCCCGGGGGCACCCCCUGCACCCCCGCCCUCCUAUGGGGCCACACACAGCAC2100              AUUUCAGCCCCCCAGGCCCCCACCCCCUGUCCGGGACUACUGACCAUGUGCCUCCCACUG2160              AAUGGCAGUUUCCAGGACCUCCAUUCCACUCAUCUCUGGCCUGAGUGACAGUGUCAAGGA2220              ACCCUGCUCCUCUCUGUCCUGCCUCAGGCCUAAGAAGCACUCUCCCUUGUUCCCAGUGCU2280              GUCAAAUCCUCUUUCCUUCCCAAUUGCCUCUCAGGGGUAGUGAAGCUGCAGACUGACAGU2340              UUCAAGGAUACCCAAAUUCCCCUAAAGGUUCCCUCUCCACCCGUUCUGCCUCAGUGGUUU2400              CAAAUCUCUCCUUUCAGGGCUUUAUUUGAAUGGACAGUUCGACCUCUUACUCUCUCUUGU2460              GGUUUUGAGGCACCCACACCCCCCGCUUUCCUUUAUCUCCAGGGACUCUCAGGCUAACCU2520              UUGAGAUCACUCAGCUCCCAUCUCCUUUCAGAAAAAUUCAAGGUCCUCCUCUAGAAGUUU2580              CAAAUCUCUCCCAACUCUGUUCUGCAUCUUCCAGAUUGGUUUAACCAAUUACUCGUCCCC2640              GCCAUUCCAGGGAUUGAUUCUCACCAGCGUUUCUGAUGGAAAAUGGCGGGAAUUCCUGCA2700              GCCCGGGGGAUCCACU2716                                                          __________________________________________________________________________

We claim:
 1. A method of evaluating the effectiveness of a test compoundfor modulating a human Na⁺ -dependent inorganic phosphate cotransporterprotein which method comprises:a) introducing into a mammalian host cellan expression vector comprising DNA encoding a human hBNPI proteinhaving SEQ ID NO:2; b) culturing said host cell under conditions suchthat the human hBNPI protein is expressed; c) exposing said host cellexpressing the human hBNPI protein to a test compound; and d) measuringthe change in a physiological condition known to be influenced by thebinding of native ligand to the human hBNPI protein relative to acontrol in which the transfected host cell is exposed to native ligand.2. A method of evaluating the effectiveness of a test compound formodulating a human Na⁺ -dependent inorganic phosphate cotransporterprotein compounds which method comprises:a) introducing into a mammalianhost cell an expression vector comprising DNA encoding a human Na⁺-dependent inorganic phosphate cotransporter protein having SEQ ID NO:2;b) culturing said host cell under conditions such that the human Na⁺-dependent inorganic phosphate cotransporter protein is expressed; c)exposing said host cell expressing the human Na⁺ -dependent inorganicphosphate cotransporter protein to a test compound; d) exposing saidhost cell expressing the Na⁺ -dependent inorganic phosphatecotransporter protein to inorganic phosphate simultaneously with orfollowing the exposure to the test compound; and e) measuring the changein inorganic phosphate uptake relative to a control in which thetransfected host cell is exposed to only inorganic phosphate.